Methods of use and combinations

A method for treating and/or preventing a disorder or condition in a subject, wherein the disorder or condition is selected from the group consisting of cachexia;

• and cachexia associated with cancer, comprising administering to said subject an effective amount of a compound of Formula 1, Formula 2 or Formula 3,
• wherein A is N or —CR0—, where R0 is hydrogen, C1-C6 linear or branched chain alkyl, C1-C6 linear or branched chain perfluoroalkyl, aryl, perfluoroaryl, alkylaryl, heteroaryl;
• or, alkylheteroaryl;
• X and Y are independently —CH2—, —CHRa—, or, —CRaRb—, where Ra and Rb are independently C1-C6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or, alkylheteroaryl;
• or, Ra and Rb together form a chain comprising —(CH2)j—, —(CHRc)j—, or —(CRcRd)j—, where Rc and Rd are independently C1-C6 linear or branched chain alkyl, C1-C6 linear or branched chain perfluoroalkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl;
• where j is 2;
• 3, 4 or 5;
• Z is —CRe—, or, —N—, where Re is hydrogen, C1-C6 linear or branched chain alkyl, C1-C6 linear or branched chain perfluoroalkyl, aryl, alkylaryl, heteroaryl or, alkylheteroaryl;
• R1 is hydrogen, C1-C6 linear or branched chain alkyl, aryl, C1-C6 linear or branched chain perfluoroalkyl, alkylaryl, heteroaryl, alkylheteroaryl, C1-C6 linear or branched chain alkoxylcarbonyl, C1-C6 linear or branched chain alkylamino-carbonylamino, C1-C6 linear or branched chain alkyloxycarbonylamino, C1-C6 linear or branched chain alkylcarbonylamino, or, C1-C6 linear or branched chain alkylaminocarbonyl;
• R2 are independently hydrogen or C1-C6 linear or branched chain alkyl;
• R3 and R4 are independently hydrogen, C1-C6 linear or branched chain alkyl, C1-C6 linear or branched chain perfluoroalkyl, C1-C6 linear or branched chain perfluoroalkoxy, halogen, cyano, hydroxyl, amino, carboxy, hydroxyl, aryl, heteroaryl, C1-C6 linear or branched chain alkoxylcarbonyl, C1-C6 linear or branched chain alkylamino-carbonylamino, or, C1-C6 linear or branched chain alkylaminocarbonyl;
• R5 and R6 are independently hydrogen or C1-C6 linear or branched chain alkyl, C1-C6 linear or branched chain perfluoroalkyl, cyano, hydroxyl, amino, carboxy, hydroxyl, aryl, heteroaryl, or, R5 and R6 together form a chain comprising —(CH2)k—, —(CHR7)k—, or —(CR7aR7b)k—, where R7, R7a, and R7b are independently C1-C6 linear or branched chain alkyl, C1-C6 linear or branched chain perfluoroalkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl;
• where k is 2;
• 3, 4 or 5;
• R8 is hydrogen, C1-C6 linear or branched chain alkyl, C1-C6 linear or branched chain perfluoroalkyl, aryl, aryl substituted with one, two or three fluorine atoms, perfluoroaryl, alkylaryl, heteroaryl;
• or, alkylheteroaryl;
• or, R1 and R8 together form a chain comprising —(CH2)m—, —(CHRf)m—, or —(CRfRg)m—, where Rf and Rg are independently C1-C6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl;
• where m is 2;
• 3, 4 or 5;
• R9 and R10 are independently hydrogen or C1-C6 linear or branched chain alkyl, C1-C6 linear or branched chain perfluoroalkyl, cyano, hydroxyl, amino, carboxy, hydroxyl, aryl, heteroaryl, or, R9 and R10 together form a chain comprising —(CH2)p—, —(CHRh)p—, or —(CRhRi)p—, where Rh and Ri are independently C1-C6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl;
• where p is 2;
• 3, 4 or 5;
• Q is —CO—, —(CH2)q—, —(CHRs)q—, or —(CRsRt)q—, where Rs and Rt are independently C1-C6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl;
• where q is 0, 1, 2, or 3;
• and, where n is 0, 1, 2, 3, 4 or 5;
• or, a pharmaceutically acceptable salt thereof.